Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer

Ítems similars

• Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer
  per: Priceman, Saul J., et al.
  Publicat: (2017)
• Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis
  per: Priceman, Saul, et al.
  Publicat: (2015)
• Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
  per: Park, Anthony K, et al.
  Publicat: (2015)
• Smart CARs Engineered for Cancer Immunotherapy
  per: Priceman, Saul J., et al.
  Publicat: (2015)
• Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy
  per: Jonnalagadda, Mahesh, et al.
  Publicat: (2013)